[go: up one dir, main page]

MX2012015279A - Derivado de tetrahidrocarbonila. - Google Patents

Derivado de tetrahidrocarbonila.

Info

Publication number
MX2012015279A
MX2012015279A MX2012015279A MX2012015279A MX2012015279A MX 2012015279 A MX2012015279 A MX 2012015279A MX 2012015279 A MX2012015279 A MX 2012015279A MX 2012015279 A MX2012015279 A MX 2012015279A MX 2012015279 A MX2012015279 A MX 2012015279A
Authority
MX
Mexico
Prior art keywords
tetrahydrocarbonila
derived
drugs
enpp2
ineffective
Prior art date
Application number
MX2012015279A
Other languages
English (en)
Inventor
Shingo Nakatani
Akira Ohata
Tetsuya Sugiyama
Takashi Morimoto
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of MX2012015279A publication Critical patent/MX2012015279A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Como un producto farmacéutico útil para pacientes con trastornos de evacuación de orina para quienes los fármacos convencionales son inefectivos, se describe un fármaco que tiene actividad inhibitoria en ENPP2, que es un objetivo diferente al de los fármaco existentes. Se describen un compuesto representado por la fórmula (I).
MX2012015279A 2010-07-06 2011-07-05 Derivado de tetrahidrocarbonila. MX2012015279A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010154280 2010-07-06
JP2011060765 2011-03-18
PCT/JP2011/065312 WO2012005227A1 (ja) 2010-07-06 2011-07-05 テトラヒドロカルボリン誘導体

Publications (1)

Publication Number Publication Date
MX2012015279A true MX2012015279A (es) 2013-04-29

Family

ID=45441206

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012015279A MX2012015279A (es) 2010-07-06 2011-07-05 Derivado de tetrahidrocarbonila.

Country Status (22)

Country Link
US (3) US9006246B2 (es)
EP (2) EP2592081B1 (es)
JP (2) JP5821848B2 (es)
KR (1) KR101831005B1 (es)
CN (1) CN102971318B (es)
AU (1) AU2011274970C1 (es)
BR (1) BR112012031580A2 (es)
CA (1) CA2802216C (es)
DK (1) DK2592081T3 (es)
ES (2) ES2693247T3 (es)
IL (1) IL223028A0 (es)
MX (1) MX2012015279A (es)
MY (1) MY161001A (es)
NZ (1) NZ603575A (es)
PH (1) PH12012502447A1 (es)
PL (1) PL2592081T3 (es)
PT (1) PT2592081T (es)
RU (1) RU2572818C2 (es)
SG (1) SG186826A1 (es)
TW (2) TWI525092B (es)
WO (1) WO2012005227A1 (es)
ZA (1) ZA201300032B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ603575A (en) 2010-07-06 2014-03-28 Ono Pharmaceutical Co Tetrahydrocarboline derivative
US9353113B2 (en) 2011-03-18 2016-05-31 Ono Pharmaceutical Co., Ltd. Tetrahydrocarboline derivative
WO2015002755A2 (en) * 2013-06-21 2015-01-08 The Broad Institute, Inc. Compounds for the treatment of malaria
WO2015163435A1 (ja) 2014-04-24 2015-10-29 田辺三菱製薬株式会社 新規２－アミノ－ピリジン及び２－アミノ－ピリミジン誘導体及びその医薬用途
US10144732B2 (en) 2014-06-06 2018-12-04 Biogen Ma Inc. ATX modulating agents
GB201501870D0 (en) 2015-02-04 2015-03-18 Cancer Rec Tech Ltd Autotaxin inhibitors
GB201502020D0 (en) 2015-02-06 2015-03-25 Cancer Rec Tech Ltd Autotaxin inhibitory compounds
US10118904B2 (en) 2015-06-05 2018-11-06 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of Demyelinating Diseases
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
WO2018195163A1 (en) 2017-04-18 2018-10-25 Gemphire Therapeutics Inc. Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor
CN110483424A (zh) * 2018-06-11 2019-11-22 上海睿升化工科技有限公司 一种1-h-1,2,3-三氮唑-4-羧酸叔丁酯的制备方法
SG11202012524YA (en) 2018-07-27 2021-01-28 Mitsubishi Tanabe Pharma Corp Novel 3, 5-disubstituted pyridine and 3, 5-disubstituted pyridazine derivatives and pharmaceutical use of same
US10947253B2 (en) 2019-08-05 2021-03-16 Ankh Life Sciences Limited Fused polycyclic dimers
CN111272918A (zh) * 2020-03-31 2020-06-12 广西-东盟食品检验检测中心 一种那非类医药中间体的高效液相色谱-质谱检测方法
CN111454260B (zh) * 2020-05-25 2023-02-28 贵州大学 一类含异丙醇胺亚结构的1，2，3，4-四氢-β-咔啉类化合物及其制备方法和应用
US12129265B2 (en) 2020-07-21 2024-10-29 Ankh Life Sciences Limited Therapeutic agents and uses thereof
JP2025163312A (ja) * 2022-09-06 2025-10-29 小野薬品工業株式会社 ジアシルグリセロールキナーゼαおよび／またはζ阻害活性を有する化合物およびその医薬用途
CN115728428B (zh) * 2022-11-15 2025-03-04 山东省医药工业设计院有限公司 一种他达拉非中间体顺式四氢咔啉盐酸盐有关物质的测定方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL130238A0 (en) * 1999-06-01 2000-06-01 Peptor Ltd Conformationally constrained backbone cyclized interleukin-6 antagonists
UA74826C2 (en) * 2000-05-17 2006-02-15 Ortho Mcneil Pharm Inc ?-carboline derivatives as phosphodiesterase inhibitors
EP1313736B1 (en) 2000-06-26 2005-07-27 Lilly Icos LLC Condensed pyrazindione derivatives as inhibitors of pde5
DE60216233T2 (de) 2001-02-12 2007-09-27 Lilly Icos Llc, Wilmington Carbolinderivate
US7285680B2 (en) 2002-05-28 2007-10-23 Ono Pharmaceutical Co., Ltd. β-alanine derivatives and the use thereof
JP4671123B2 (ja) 2003-06-23 2011-04-13 小野薬品工業株式会社 新規三環性複素環化合物
JP2007518822A (ja) * 2004-01-23 2007-07-12 カイロン コーポレイション 抗癌剤としてのテトラヒドロカルボリン化合物
TW200539880A (en) 2004-04-09 2005-12-16 Millennium Pharm Inc Beta-carbolines useful for treating inflammatory disease
JP4997976B2 (ja) * 2004-12-22 2012-08-15 小野薬品工業株式会社 三環式化合物およびその用途
JP2008297278A (ja) 2007-06-01 2008-12-11 Astellas Pharma Inc Ｌｐａ受容体アゴニスト
NZ603575A (en) 2010-07-06 2014-03-28 Ono Pharmaceutical Co Tetrahydrocarboline derivative
US9353113B2 (en) 2011-03-18 2016-05-31 Ono Pharmaceutical Co., Ltd. Tetrahydrocarboline derivative

Also Published As

Publication number Publication date
ES2623286T3 (es) 2017-07-10
CN102971318A (zh) 2013-03-13
EP3002285A1 (en) 2016-04-06
US20170189386A1 (en) 2017-07-06
DK2592081T3 (en) 2017-06-06
US20130109699A1 (en) 2013-05-02
TW201215611A (en) 2012-04-16
AU2011274970C1 (en) 2015-07-30
RU2572818C2 (ru) 2016-01-20
CA2802216A1 (en) 2012-01-12
BR112012031580A2 (pt) 2016-11-08
AU2011274970B2 (en) 2015-03-05
JP6065052B2 (ja) 2017-01-25
CN102971318B (zh) 2015-11-25
AU2011274970A1 (en) 2013-01-24
ES2693247T3 (es) 2018-12-10
US20150231118A1 (en) 2015-08-20
TW201623306A (zh) 2016-07-01
CA2802216C (en) 2018-12-11
SG186826A1 (en) 2013-02-28
PL2592081T3 (pl) 2017-07-31
WO2012005227A1 (ja) 2012-01-12
IL223028A0 (en) 2013-02-03
NZ603575A (en) 2014-03-28
JP5821848B2 (ja) 2015-11-24
EP2592081A1 (en) 2013-05-15
EP3002285B1 (en) 2018-08-29
KR101831005B1 (ko) 2018-02-21
US9974777B2 (en) 2018-05-22
EP2592081A4 (en) 2014-05-07
ZA201300032B (en) 2013-09-25
JPWO2012005227A1 (ja) 2013-09-02
EP2592081B1 (en) 2017-03-08
TWI525092B (zh) 2016-03-11
JP2015214544A (ja) 2015-12-03
US9006246B2 (en) 2015-04-14
PH12012502447A1 (en) 2016-10-14
US9636330B2 (en) 2017-05-02
RU2013104866A (ru) 2014-08-20
PT2592081T (pt) 2017-05-03
KR20130098269A (ko) 2013-09-04
MY161001A (en) 2017-03-31
TWI586666B (zh) 2017-06-11

Similar Documents

Publication Publication Date Title
MX2012015279A (es) Derivado de tetrahidrocarbonila.
UY38712A (es) Lactamas fusionadas de arilo y heteroarilo
DOP2017000013A (es) Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
CL2014000566A1 (es) Compuestos derivados de pirrolopirimidina y purina, y sus sales farmaceuticamente aceptables; composicion farmaceutica que los comprende, util para el tratamiento del crecimiento celular anormal, tal como cancer.
PE20180318A1 (es) Procedimiento para preparar isoquinolinonas y formas solidas de isoquinolinonas
BR112015011112A2 (pt) composto oligomérico, oligômero, composição farmacêutica, uso do composto oligomérico, método de síntese de um composto oligomérico e método de tratamento de uma doença.
CL2014000642A1 (es) Compuestos derivados de indazol-3-carboxamidas, como inhibidores de la ruta de señalizacion de wnt/b-catenina; composicion farmaceutica que los comprende; y su uso para el tratamiento de cancer, artritis reumatoide, infecciones micoticas y viricas, enfermedad de parkinson, un trastorno fibrotico, entre otras enfermedades.
ECSP14013325A (es) Piridopirazinas anticancerigenas via la inhibicion de cinasas del receptor del factor de crecimiento de fibroblasto (fgfr)
CR20140161A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
CO6531458A2 (es) Nuevos compuestos de espiropiperidina
CO6480932A2 (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida.
PE20150887A1 (es) Compuestos de benceno sustituidos
CR20120296A (es) Nuevos compuestos de espiropiperidina
MX2016003199A (es) Compuestos de azapiridona y usos de los mismos.
UY33199A (es) 5-alquinil-pirimidinas.
CL2014001049A1 (es) Compuestos derivados de purina sustituida, inhibidores de mtor; composicion farmaceutica; combinacion farmaceutica; uso para el tratamiento o prevencion del cancer, un trastorno neurodegenerativo o una enfermedad oftalmologica.
UY33817A (es) ?nuevas oxindolpirimidinas bencílicas?.
CO6480975A2 (es) Mimetico de smac
GEP20156347B (en) Benzodioxane inhibitors of leukotriene production
CO7310531A2 (es) 4-metil-2,3,8,9,9b-pentaaza-ciclopenta [a] naftalenos
AR087451A1 (es) Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes
CU20110088A7 (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), producción y uso de los mismos como productos medicinales
ECSP14002542A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
CL2014000393A1 (es) Compuestos derivados de benzofurano y sus sales, como inhibidores del virus de hepatitis c; composicion farmaceutica que los comprende; y su uso para el tratamiento o la prevencion de una infeccion por el virus de hepatitis c o de una enfermedad asociada con dicha infeccion.
UY33529A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias?

Legal Events

Date Code Title Description
FG Grant or registration